A topical hair loss medication successfully built up hair in a Phase 3 trial, according to the results of two late stage trials released Wednesday.

Cosmo Pharmaceuticals, which is based in Dublin, ran the studies on men with a common form of hair loss called androgenetic alopecia. The company reported that men who used Cosmo’s drug clascoterone had more hair after six months than the men in a placebo group — 168% more hair in one trial and 539% in another.

Cosmo anticipates filing for regulatory approvals in the U.S. and Europe next year, after it gathers the full 12-month safety data in the spring.

To read the rest of this story subscribe to STAT+. Subscribe Log In

See Full Page